The American Urological Association (AUA) has announced three updates to the organization’s guideline on the management of castration-resistant prostate cancer (CRPC). All the modifications are specific to the potential uses of radium-223 in men with late stage metastatic disease.
The three updates are:
- Clinicians should offer radium-223 to patients with symptomatic, metastatic CRPC (mCRPC) with good performance status and no prior docetaxel chemotherapy with symptomatic bone metastases and without known visceral disease (Standard; Evidence Level Grade B).
- Clinicians may offer radium-223 to patients with symptomatic mCRPC with poor performance status and no prior docetaxel chemotherapy with symptomatic bone metastases and without known visceral disease in select casts, specifically when the performance status is directly related to symptoms related to bone metastases (Expert Opinion).
- Clinicians should offer radium-223 to patients with good performance status who received prior docetaxel chemotherapy with symptomatic bone metastases and without known visceral disease (Standard; Evidence Level Grade B).
The use of bold italic text to emphasize specific verbs is the dsecision of The “New” Prostate Cancer InfoLink ands did not poccur in the AUA’s original media release.
The full AUA guideline for the management of CRPC, including these new amendments, is available on line.
Filed under: Uncategorized |
THE "NEW" PROSTATE CANCER INFOLINK 
I wish I could have had my father on this when he had prostate cancer